Core Viewpoint - CRISPR Therapeutics AG has announced a private offering of $550 million in convertible senior notes due 2031, which was upsized from a previously announced $350 million offering [1][7] Group 1: Offering Details - The offering is targeted at qualified institutional buyers under Rule 144A of the Securities Act [1] - The notes will have an effective coupon of 1.125%, increased to 1.7308% due to anticipated Swiss tax withholding [2] - Interest payments will be made semiannually starting September 1, 2026, with maturity on March 1, 2031 [2] Group 2: Conversion and Redemption - Holders can convert their notes into common shares at a conversion rate of 13.0617 shares per $1,000 principal amount, equating to an initial conversion price of approximately $76.56 per share [3][4] - The conversion price represents a 45% premium over the last reported sale price of $52.80 per share on March 10, 2026 [4] - The company may redeem the notes starting March 6, 2029, under specific conditions related to the stock price [5] Group 3: Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $536.3 million, or $585.2 million if the option for additional notes is fully exercised [7] - The proceeds will be used for general corporate purposes [7] Group 4: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on gene-based medicines for serious diseases, with a notable achievement being the approval of CASGEVY, the first CRISPR-based therapy [10] - The company is advancing a diversified pipeline across various therapeutic areas and has established strategic collaborations with major biopharmaceutical partners [10]

Core Insights - CRISPR Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT in San Francisco [1] Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on developing gene-based medicines for serious diseases, evolving from a research-stage organization to an industry leader [3] - The company achieved a historic milestone with the approval of CASGEVY (exa-cel), the world's first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia [3] - CRISPR Therapeutics has a diversified pipeline targeting hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune diseases, and rare diseases [3] - The company is advancing its gene editing capabilities through the development of SyNTase™, a proprietary platform for precise and efficient gene correction [3] - Strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals, are established to enhance its impact [3] - The company is headquartered in Zug, Switzerland, with R&D operations in Boston, Massachusetts, and San Francisco, California [3]

Core Insights - CRISPR Therapeutics presented promising preclinical data for CTX460, a novel gene editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), at the ESGCT 2025 Annual Congress, indicating a potential best-in-class profile [1][2][6] - The company plans to initiate clinical trials for CTX460 in mid-2026, marking a significant advancement in gene-based therapies for AATD [1][2] Preclinical Data Highlights - CTX460 demonstrated over 90% mRNA correction and a 5-fold increase in total AAT levels in AATD disease models, with a serum M-AAT:Z-AAT ratio exceeding 99% [1][5] - A single dose of CTX460 achieved significant liver DNA correction in both rat and mouse models, with effective editing observed at doses as low as 0.1 mg/kg [5] - The durability of the editing effect was maintained for up to 7 weeks in rats and 9 weeks in mice, supporting the long-term efficacy of the treatment [5] AATD Background - AATD is primarily caused by a mutation in the SERPINA1 gene, leading to insufficient functional AAT levels, which increases the risk of lung diseases such as emphysema [2][3] - Current treatments do not address the genetic cause of AATD, highlighting the need for innovative therapies that can normalize AAT levels [3][4] SyNTase Editing Platform - CTX460 utilizes the SyNTase editing platform, encapsulated in a proprietary lipid nanoparticle, targeting the E342K mutation in SERPINA1 [4][6] - The preclinical models used for evaluation included the NSG-PiZ mouse model and a humanized PiZ rat model, demonstrating the platform's potential for gene correction [4][6] Company Overview - CRISPR Therapeutics has evolved into a leader in gene editing, with a diverse portfolio across various disease areas, including hemoglobinopathies and rare diseases [7] - The company has made significant strides in advancing CRISPR technology, including the approval of the first CRISPR-based therapy, CASGEVY, for sickle cell disease and beta thalassemia [7]